In pooled data from the sword 1 and sword 2 studies, 89% (456/513) of participants on the 2-drug regimen of dolutegravir and rilpivirine for 100 weeks (n=513) maintained viral suppression, with a viral load of less than 50 copies/ml. Phase iii trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (arv)-naïve patients and found dolutegravir to achieve more rapid and sustained virologic suppression in both instances. Domono, an open-label, phase 2 trial, assessed the non-inferiority of dolutegravir monotherapy to combination art for maintenance of virologic suppression in patients with hiv-1 infection who had been treated successfully with combination art. An intriguing simplification strategy for individuals with stable hiv suppression number of virologic failures drug-drug interactions4-5 dolutegravir (dtg . A possible alternative and intriguing simplification strategy for individuals with stable hiv suppression on cart is the use of a dual therapy based on dolutegravir plus lamivudine, a potent cytidine nucleoside analogue without major side effects, and that has a well-proven safety profile 7.
Drug–drug interactions dolutegravir is a substrate for the efflux transporters p glycoprotein and the human breast cancer resistance protein, but it has high membrane permeability, which reduces the effects that transporters will have on its transmembrane movements. Dolutegravir has minimal drug-drug interactions and pharmacokinetic variability for regimen switching in the setting of virologic suppression 3 two drug . Today viiv healthcare presented 100-week results from 2 phase 3 studies of the safety and efficacy of dolutegravir and rilpivirine the sword studies are evaluating the long-term effects of switching patients with hiv who are virologically suppressed from a 3- or 4-drug antiretroviral regimen to the . Switching to [dolutegravir + lamivudine] combination maintained virologic suppression at week 40 [and] was safe and well-tolerated in this population of selected patients without previous virological failure, the researchers concluded.
The 2-drug regimen comprises dolutegravir 50mg (viiv healthcare) and rilpivirine 25mg (janssen sciences ireland uc) virologic suppression rates were similar . Dolutegravir plus lamivudine appears to be efficacious for maintenance of hiv virologic suppression and the tango trial will be a large phase 3 randomized trial to confirm this 2-drug strategy advertisement. Virologic failure and hiv drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis [version 1 referees: awaiting peer review].
Durable virologic suppression maintained with 1% of subjects receiving dolutegravir in phase 3 or loss of virologic response due to drug interactions: . The once-daily pill can maintain viral suppression in patients on a stable antiretroviral regimen with no known or suspected resistance to a non-nucleoside reverse transcriptase inhibitor or . Ninety-five percent of patients maintained a high level of virologic suppression through week 48 the cohort on the two-drug regimen of dolutegravir and . Lower virologic suppression rates and increased risk of viral resistance were observed in pediatric subjects who received epivir oral solution concomitantly with other antiretroviral oral .
Although dolutegravir (dtg) is known for its high genetic barrier to resistance, its durability to maintain virologic suppression had not previously been evaluated typically, effective art consists of 3 antiretrovirals (arvs) from at least 2 drug classes. In virologically suppressed individuals with hiv-1, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance therapy, according to a study published in clinical infectious diseases researchers in the pilot dolutegravir antiretroviral strategy to promote . Another study at the conference showed that switching from a three-drug regimen to a dual combination of dolutegravir plus lamivudine (3tc or epivir) maintained viral suppression for 40 weeks lamivudine is a well tolerated nucleoside reverse transcriptase inhibitor (nrti) that is available in low-cost generic versions worldwide.
Drug interactions with antiretroviral medications dolutegravir-rilpivirine (juluca) other names: dtg-rpv switch to dtg+rpv maintains virologic suppression . In this pilot, proof of concept study, dual therapy with dolutegravir plus lamivudine induced rapid virologic suppression with a favourable safety/tolerability profile in hiv-1 infected, treatment-naive individuals, the researchers concluded. In pooled data from the sword 1 and sword 2 studies, 89% (456/513) of participants on the 2-drug regimen of dolutegravir and rilpivirine for 100 weeks (n=513) maintained viral suppression, with a .
Janssen announces two-drug combination of dolutegravir and rilpivirine demonstrates efficacy in maintaining viral suppression in phase iii clinical studies. Milestones in the treatment of 3-drug regimens achieve virologic suppression with hypersensitivity reactions have been reported with dolutegravir and were . The findings by wijting et al raise a cautionary warning against the headlong switch to dolutegravir-based regimens among patients currently receiving efavirenz-based art in resource-limited settings, unless virus load testing can be performed at the time of switching, to confirm virologic suppression. Juluca (dolutegravir, rilpivirine viiv healthcare) maintained viral suppression through 100 weeks in virologically suppressed people living with hiv who switched to the 2-drug regimen from a 3 or .